Market Overview

Guggenheim Downgrades Cadence Pharmaceuticals, Inc. to Neutral, Maintains $15.00 PT

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for CADX

DateFirmActionFromTo
Feb 2014GuggenheimDowngradesBuyNeutral
Feb 2014GuggenheimDowngradesBuyNeutral
Feb 2014WedbushDowngradesOutperformNeutral

View More Analyst Ratings for CADX
View the Latest Analyst Ratings

Posted-In: News Downgrades Analyst Ratings

 

Related Articles (CADX)

Partner Center